The first of these is a broad-based policy document representing the Government’s view of how best it can work with business and the wider community to create jobs, and increase growth and productivity. Its policies include commitments to increased R&D expenditure, improvements in technical education and availability of people with STEM (Science, Technology, Engineering and Mathematics) skills, transport and digital infrastructure investment, and regional initiatives. At its heart though, is what they term ‘business environment’ policy which reflects the reliance of the UK economy on certain high value-add world-class industrial sectors such as life sciences, automotive, technology, and construction alongside improving the relatively low productivity of much of the rest. The approach laid out is rational and coherent, and had been broadly welcomed by industry. Since some unfortunate state interventions in the 1970s, there has been a reluctance for government to be seen to get involved for fear of meddling in the market - although it has to be said that successive administrations have taken positive steps to make the UK by common consent to be one of the best places in the world to do business. The truth is though, as has been seen in the US, new industries emerge in environments where governments, universities, investors and industrialists/entrepreneurs work closely together and barriers to translation of ideas through to the market are minimised. To do this requires a strategy to be drawn up, supported and monitored. 0066山師さん@トレード中 (ワッチョイ 898e-XhTK)2018/01/16(火) 16:00:17.92ID:fFyMoZfN0 Turning to our principle subject of interest - the life sciences sector - the ‘deal’ follows hard on the heels of the review by Sir John Bell and colleagues and largely seems to commit to its recommendations. The life sciences sector is very strong in the UK in spite of the trend to pharma downsizing, which has been to a large degree balanced by the growth in biotechnology - Oxford, Cambridge and London being the third largest global biomedical and biotechnology cluster (after Greater Boston and San Francisco). This growth has come hand in hand over the past 20 years with improved tax incentives, direct grant funding, increased management expertise, facilities, technology transfer and so forth - all built on top of a world class biomedical science base with critical mass.
As well as at very least preserving these advances, key issues remain to be addressed and are discussed in the document. Getting the most from the NHS by facilitating clinical trials and accelerating access to innovative new medicines through the Accelerated Access Collaborative would make a big difference to all parties (biomedical, industrial and patient) and could make the UK consistently a territory of choice for drug development. Easy, rapid recruitment and a welcoming environment for skilled people from overseas (obviously post-Brexit for EU people, but ultimately the pool is global) is critical both for academia and industry, especially rapidly growing specialised start-ups. Greater investment held for longer periods (‘patient capital’) by the likes of pension funds and from specialist healthcare funds is needed to enable small companies to scale up. Apprenticeship schemes will be used to address skills gaps. There are a variety of other initiatives laid out in the document which can be skim-read quite easily. 0067山師さん@トレード中 (ワッチョイ 898e-XhTK)2018/01/16(火) 16:00:34.41ID:fFyMoZfN0 In summary, the Life Science Sector Deal has as far as I can see been well received by the various stakeholders and should probably be declared a ‘good thing’. Some of it is about ways of working together, which is about being bothered and making things happen. Much of it requires continued or increased committed public and private funding, which of course in turn depends on the UK’s economic performance and on competing pressures for money. Obviously there is much concern about Brexit, but that will pass and there is reason for optimism that a sensible deal will be struck. Whatever happens in the wider political landscape it is vital we make the most of the opportunities that present themselves.
Malcolm is Chief R&D Officer of Sosei and CEO of Heptares, its wholly-owned subsidiary. Following many years in Glaxo Wellcome and in biotech, he co-Founded Heptares in 2007 with Fiona Marshall, Chris Tate and Richard Henderson (MRC Laboratory of Molecular Biology, Cambridge) based on unique technology for structure-based drug design to G protein-coupled receptors. The company now has drugs in the clinic for Alzheimer’s Disease, Dementia with Lewy Bodies, psychosis and cancer. He is Visiting Professor of Biochemistry at Imperial College London, where he received BSc and PhD degrees in Biochemistry and Chemistry. He is a Fellow of the Royal Society of Chemistry and received the RSC’s Malcolm Campbell Memorial Prize in 2015, and an Honorary DSc from the University of Hertfordshire in 2016. He is a Trustee of the Biochemical Society. 0068山師さん@トレード中 (ワッチョイ 898e-XhTK)2018/01/16(火) 16:01:35.52ID:fFyMoZfN0 ※みんなの株式:【買い】そーせいグループ(4565)深刻的疾患に一石を投じる◆あすなろ投資顧問 加藤あきら◆ 1/16 08:42 深刻的疾患に一石を投じる 独自の創薬基盤技術を軸に、日英2拠点体制でバイオ医薬品を研究開発する創薬系のバイオベンチャー。ノバルティスと提携し慢性閉塞性肺疾患(COPD)治療薬「シーブリ」「ウルティブロ」を上市する。 11月9日の決算、18年3月期2Qの連結経常損益は8.8億円の赤字であったが、売上営業損益率は前年同期の-96.7%から28.2%に大きく改善した。 同社の売上収益は提携契約によるマイルストン収益に依存しており、提携先の開発戦略及び開発スケジュールに影響されるため、当社グループがマイルストンを受領する時期を予想することは困難、会計年度ごとの売上収益額に大きな変動が生じる可能性があるとしている。 1月11日に子会社のHeptares社とインペリアル・カレッジ・ロンドンが、複数年の戦略的提携により、消化器疾患に関連する新規及び既知のGタンパク質共役受容体(GPCR)をターゲットとした治療薬の創薬、 また、トランスレーショナルリサーチを行うため、相互補完的なチームを結成して共同研究開発を進めると発表。死因第3位の深刻な疾患に対し、一石を投じることにより、今後の業績の巻き返しに期待したい。 チャート面では昨年12月から保ち合いを形成し、一旦12200円台まで上放れた後5日線まで押す展開に。同移動平均線を底堅く維持していることから、押し目買いを狙った個人投資家の買いが入り、昨年11月の高値12380円の上抜けを期待したい。 0069山師さん@トレード中 (ワッチョイ 898e-XhTK)2018/01/16(火) 16:02:25.35ID:fFyMoZfN0 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。 成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。 Heptares Approach Extends well Beyond our Growing Pipeline. UK be Relocating to the Cambridge Area in "July 2018." ・・・ Bloomberg:創薬ベンチャーのそーせいは買収を通じて業容を拡大し、株価は過去2年間で約300%上昇(2015/3/17終値_2972→2017/3/17終値10750)。 2015/_2/20 (終値_3780) 売残高14200 買残高 1530800 ・(2015/2/21Heptares子会社化: 2015/3/16※最安値2851)※[成功の序章ステージへ] 2015/10/30 (終値_4320) 売残高11400 買残高 2217900 ・(2015/9/24※安値3550) (2015/10/29※終値3885:Utibron・Seebri米国承認)※[次なる飛躍ステージへ] 2016/_4/25 (終値23230) 売残高39800 買残高 3404900 ・(2016/4/6終値14180:Allergan)※[強気相場へ]→(2016/5/9※最高値26180)→ 2016/_6/24 (終値14720) 売残高10500 買残高 2486100 ・(2016/6/24安値12960)※[強気相場解除]→※[時間軸での調整局面へ] ※2016年大納会(2016/12/30終値13450) 2017/_1/_6 (終値14030) 売残高__300 買残高 2907100 ・(2017/1/24安値12910、2/13安値12400)※[強気相場解除後の時間軸調整は順調に推移] 2017/_3/31 (終値10880) 売残高_5600 買残高 2621800 ・(3/1安値10380、4/4安値10280、5/23安値10810、6/7安値10960)※[振るい場・拾い場へ] 2017/_9/_8 (終値_8700) 売残高_1900 買残高 2037800 ・(7/31安値11280、8/24,29安値_8860、9/6※最安値_8590)※[拾い場も順調に推移] 2017/11/17 (終値12190) 売残高_3100 買残高 1532100 ・(9/11安値_8630、10/4安値_9090、11/8安値10310)※[時間軸調整終盤、予定通りに推移] 2017/12/29 (終値10940) 売残高__300 買残高 1634900 ※2017年大納会(安値10730) ・(12/6安値_9970) _1/_4 (終値10800)5日線乖離(+0.30%) 25日線乖離(_+1.30%) 75日線乖離(_+4.71%) 200日線乖離(_+0.36%) (安値10760) ※2018年大発会 _1/_5 (終値10730) 5日線乖離(-1.07%) 25日線乖離(_+0.94%) 75日線乖離(_+3.78%) 200日線乖離(_-0.22%) (安値10530) _1/_9 (終値11550) 5日線乖離(+5.46%) 25日線乖離(_+8.47%) 75日線乖離(+11.31%) 200日線乖離(_+7.40%) (安値10760) _1/10 (終値11890) 5日線乖離(+6.33%) 25日線乖離(+11.28%) 75日線乖離(+14.15%) 200日線乖離(+10.55%) (安値11710) _1/11 (終値11540) 5日線乖離(+2.11%) 25日線乖離(_+7.74%) 75日線乖離(+10.41%) 200日線乖離(_+7.25%) (安値11460) _1/12 (終値11700) 5日線乖離(+1.90%) 25日線乖離(_+8.74%) 75日線乖離(+11.54%) 200日線乖離(_+8.71%) (安値11470) _1/15 (終値11750) 5日線乖離(+0.55%) 25日線乖離(_+8.55%) 75日線乖離(+11.67%) 200日線乖離(+9.12%) (安値11630) _1/16 (終値11740) 5日線乖離(+0.14%) 25日線乖離(_+7.75%) 75日線乖離(+11.21%) 200日線乖離(+9.00%) (安値11380)
※Heptares_HP_Publications: Add. (1/16update) ・"Structure of the complement C5a receptor bound to the extra-helical antagonist NDT9513727". Nature 2018. ・"Agonists and Antagonists of Protease-Activated Receptor 2 Discovered within a DNA-Encoded Chemical Library Using Mutational Stabilization of the Target". SLAS 2018. ・"Towards high throughput GPCR crystallography: In Meso soaking of Adenosine A2A Receptor crystals". Scientific Reports 2018. ・"Structural Mapping of Adenosine Receptor Mutations: Ligand Binding and Signaling Mechanisms". Trends Pharmacol. Sci. 2018. ・・・ 0072山師さん@トレード中 (ワッチョイ 790f-Un5q)2018/01/16(火) 17:38:57.87ID:kcMAqtms0 世界から隔離された日本株主 0073山師さん@トレード中 (アウアウウー Sa21-DkVE)2018/01/16(火) 17:59:54.47ID:P4DxZJp+a 英文ホームページに資料来とる。 http://v4.eir-parts.net/v4Contents/View.aspx?template=ir_material_for_fiscal_ym&sid=44192&code=4565 0074山師さん@トレード中 (アウアウカー Sa55-ic3a)2018/01/16(火) 18:13:22.91ID:7BFvBBJya>>73 大した内容じゃないな 0075山師さん@トレード中 (スフッ Sd0a-ucrw)2018/01/16(火) 18:16:31.53ID:pxtOwF5fd>>73 ほぼ予定通りやんけ A2aが順調にP1a終わってP1bやってるって予想通り 0076山師さん@トレード中 (スフッ Sd0a-ucrw)2018/01/16(火) 18:19:04.36ID:pxtOwF5fd こんなん発表した5分後に公開するだけでええやんけ 0077山師さん@トレード中 (スッップ Sd0a-Ywka)2018/01/16(火) 19:47:54.14ID:58x0IAj8d ホルダーおめ 0078山師さん@トレード中 (ササクッテロレ Spbd-zkuo)2018/01/16(火) 19:51:23.01ID:/R9UJQ2dp ありがとう 0079山師さん@トレード中 (アウアウカー Sa55-ic3a)2018/01/16(火) 19:52:03.64ID:NsEj5AXma しかしこんなの出しておいて、どこまで嫌がらせをしたら気がすむのか? http://v4.eir-parts.net/DocumentTemp/20180116_075129675_iii5pu2xovsxcp55gykaicjj_0.pdf0080山師さん@トレード中 (ワッチョイ c597-6xgx)2018/01/16(火) 19:53:25.50ID:Fy5pJ+Ke0 被害妄想だって 0081山師さん@トレード中 (ワッチョイ 156f-53ns)2018/01/16(火) 20:16:39.51ID:2NtHy9ZC0 まあ今年も始まったばっかだからゆっくり行こうや とはいえ早く12000円越えて欲しいな 0082山師さん@トレード中 (ワッチョイ 898e-5P5V)2018/01/16(火) 21:00:11.59ID:fFyMoZfN0 ・・・ ※SOSEI (English) Presentation Material:"Introduction to SOSEI Group, July 2017": ttp://v4.eir-parts.net/v4Contents/View.aspx?template=ir_material_for_fiscal_ym&sid=37821&code=4565 (7/5up) ※Heptares Presentation:"Corporate Overview September": ttps://www.heptares.com/uploads/Heptares%20Corporate%202017%20-%20Sep.pdf (9/27up) ※Heptares: J.P.Morgan Healthcare Conference, Jan 8-11, 2018, San Francisco: "Attend: Executive Management Team (Business Development Event)" (11/9up) ※日経バイオテク:新春展望2018:そーせいを国際的なステージに展開へ。2018年はJPモルガンヘルスケアカンファレンスから活動を開始。そーせい初参加。そーせいのストーリーについて発表する予定。(1/2) ※SOSEI:サンフランシスコで開催の第36回JPモルガンAnnual Healthcare Conferenceにピーター・ベインズ出席。発表資料はイベント終了後に公開。(1/5) ※Scrip: Sosei CEO Says Recent $199m Equity Raising Will Help Pipeline Expansion: its shareholder base more international and will help finance the evolution of the group's proprietary pipeline. (1/8) ※BioWorld: Sosei lands $200M to fund six Heptares’ programs, including dementia. "placing to fund clinical development of proprietary assets discovered by its U.K. subsidiary, GPCR specialist Heptares." (1/9) ↓ ※SOSEI (English) Presentation Material:"Sosei Group Corporation, 36th Annual J.P. Morgan Healthcare Conference, 8 January 2018." (1/16 10:30up) A Japan-listed biotech with a difference: (Listed 2004 in Tokyo (TSE Mothers: 4565), Global management team, Main scientific campus in the U.K., Market capitalization: c.$2.0bn.) ・World-leader in GPCR-focused drug design based on unique IP protected StaR GPCR technology & enabled SBDD platform. ・Partnered clinical-stage pipeline in neurology, immuno-oncology, CNS & other diseases, with up to c.$6bn in potential economics. ・Proprietary pipeline led by dementia with Lewy Bodies (DLB) Phase 2 program in Japan, plus multiple novel candidates in development. ・Strategic investment in saRNA therapeutics with lead candidate in Phase 1/2a for liver cancer, an orphan indication ・Growing royalties from legacy respiratory products provide source non-dilutive cash flows. ・Strong cash position of c.$300m to drive global growth strategy: 1. Stabilized receptor technology; 2. Structure-based drug design. Tokyo listed, global operations. We are building Japan’s first biotech champion.
Three corporate events have shaped Sosei: Platform: StaR technology for stabilising GPCRs; Partnered GPCR pipeline; Proprietary GPCR pipeline. Our world-leading Partners. ・Our patent-protected StaR technology enables Structure-Based Drug Design, consolidating our position as the world leader in GPCR medicine discovery and design. Vast opportunity targeting GPCRs, however many high-value targets remain untapped: GPCRs are the backbone of the pharma industry. (GPCRs/StaR) ・GPCRs are active in a wide range of disease areas, and offer broad therapeutic potential. ・Targeting first-in-class or best-in-class GPCR medicines. StaR technology enables us to stabilize and “unlock” GPCRs: Revolution for GPCR structure-based discovery. (GPCRs/StaR) ・StaR proteins enable crystallisation for structural determination, and the technology is protected by a robust IP estate and high levels of know-how. ・StaR proteins enable SME, peptide or antibody discovery. Risk-balanced strategy to leverage leadership and capitalize on GPCR opportunity: Creates and captures value. (Business Model) ・Reserving the right to choose which strategy is most appropriate for each drug candidate, with a goal to commercialize ourselves in selected indications and markets. 0083山師さん@トレード中 (ワッチョイ 898e-5P5V)2018/01/16(火) 21:00:40.72ID:fFyMoZfN0 Advancing a Partnered GPCR pipeline in multiple therapeutic areas: Balanced and diversified. (Partnered GPCR Pipeline: Current stage, Next 12–15 months progress) ・Multiple big pharma partners, across multiple modalities, validate our StaR and SBDD approach. Up to $6bn in potential economics secured from lead Partnered compounds: Provides potential source of non-dilutive financing. (Partnered GPCR Pipeline) ・c.$6bn in potential development, regulatory and commercial milestones to come, in addition to royalties on sales Muscarinic M1 receptor agonist program for AD: A novel approach for symptomatic treatment of AD. (Partnered GPCR Pipeline: M1 AD: Phase 1b: Allergan) ・Selective muscarinic M1 receptor agonism offers a potential first-in-class therapy for AD patients. HTL0018318 is a potential first-in-class therapy for AD: Highly selective M1 receptor agonist derived from StaR and SBDD. (Partnered GPCR Pipeline: M1 AD: Phase 1b: Allergan) ・Selectivity is crucial. HTL0018318 has a differentiated mechanism of action with the potential to optimise symptomatic benefits in AD patients.
Adenosine A2A antagonist program for cancer treatment: Exciting I/O treatment approach. (Partnered GPCR Pipeline: A2A: Phase 1b: AstraZeneca) ・Immunotherapies are at the forefront of cancer treatment with strong forecast growth for I/O drugs. A2A antagonists represent an exciting I/O treatment approach. AZD4635 is a highly potent and selective A2A antagonist: The first A2A antagonist structurally derived from StaR and SBDD. (Partnered GPCR Pipeline: A2A: Phase 1b: AstraZeneca) ・AZD4635 enhances the anti-tumor activity of anti-PD-L1 checkpoint inhibitors in established MC38 syngenic tumors. Proprietary pipeline now led by M1 DLB opportunity in Japan: Focus on selected rare/orphan and specialty indications or markets. (Proprietary GPCR Pipeline: Current stage, Next 12–15 months progress) ・Investment in StaR technology driving Proprietary GPCR pipeline progress – up to 3 novel drug candidates to enter Phase 1 every year commencing CY2018. Sosei is advancing HTL0018318 for DLB in Japan: Highly selective M1 receptor agonist designed by StaR and SBDD. (Proprietary GPCR Pipeline: M1 DLB: Phase 2 ready) ・Strong go-to-market opportunity for our lead M1 program in Japan. Significant unmet medical and social need for a new therapeutic approach to tackle DLB in Japan. Strategic investment in saRNA technology: CEBPA is an attractive, previously ‘undruggable’ target in liver disease. (Strategic Investment: CEBPA Phase 1/2a: MiNA Therapeutics) ・We are excited about the potential of saRNA therapeutics. MiNA’s recent deal with Boehringer Ingelheim further supports MiNA/saRNA’s potential. 0084山師さん@トレード中 (ワッチョイ 898e-5P5V)2018/01/16(火) 21:01:11.39ID:fFyMoZfN0 Continuing to invest and scale the business: Allergan upfront milestone in FY2016 drives P&L variance. (Financials) ・PLUS c.$200m raised in November 2017 via a Global Offering of shares to international investors. ・Pro forma cash balance of c.$300m provides runway of approx. 2-3 years based on organic business plan.
Thank you!: (Listed 2004 in Tokyo (TSE Mothers: 4565), Global management team, Main scientific campus in the U.K., Market capitalization: c.$2.0bn.) ・World-leader in GPCR-focused drug design based on unique IP protected StaR GPCR technology & enabled SBDD platform. ・Partnered clinical-stage pipeline in neurology, immuno-oncology, CNS & other diseases, with up to c.$6bn in potential economics. ・Proprietary pipeline led by dementia with Lewy Bodies (DLB) Phase 2 program in Japan, plus multiple novel candidates in development. ・Strategic investment in saRNA therapeutics with lead candidate in Phase 1/2a for liver cancer, an orphan indication. ・Growing royalties from legacy respiratory products provide source non-dilutive cash flows. ・Strong cash position of c.$300m to drive global growth strategy. Sosei is a Japan-listed biotech with a difference. 0085山師さん@トレード中 (ワッチョイ 898e-5P5V)2018/01/16(火) 22:30:21.81ID:fFyMoZfN0 ・・・ ※Pluristem: Company Presentation September 2017: ttp://www.pluristem.com/wp-content/uploads/2016/04/Pluristem-September-2017.pdf ( 9/17up) ※Pluristem: Company Presentation October 2017: ttp://www.pluristem.com/wp-content/uploads/2016/04/Pluristem-Investor-deck-29.10.2017.pdf (10/29up) ↓ ※Pluristem: Company Presentation January 2018. (1/16up) A Change in Regulatory Environment: CLI (PLX-PAD): Japan, PMDA Accelerated Regulatory Pathway. Company Pipeline: Critical Limb Ischemia (CLI): Japan (Via PMDA’s accelerated regulatory pathway for regenerative therapies) Single pivotal study. Clinical Development of CLI in Japan: PMDA Japan, Sosei CVC ・Accepted to the PMDA’s accelerated regulatory pathway for regenerative therapies. ・A single 75 patient study may lead to early conditional marketing approval and reimbursement. ・Binding term sheet with Sosei CVC to establish joint venture for the clinical development and commercialization of PLX-PAD for CLI in Japan. Upcoming Milestones - 12 Months: Initiate Pivotal Studies: ・Critical limb ischemia (CLI) - U.S., Europe (Japan yet to start). Business Development: ・Japan - Finalize joint venture. http://www.pluristem.com/wp-content/uploads/2016/04/Pluristem-January-2018.pdf0086山師さん@トレード中 (アウアウカー Sa55-ic3a)2018/01/16(火) 23:12:40.38ID:PgDlIrfEa 資料ショボすぎて明日は爆下げだろうな 0087山師さん@トレード中 (スッップ Sd0a-Ywka)2018/01/17(水) 00:31:17.37ID:gWLBZ5Tyd 馬鹿は中身すら読んでないだろう 0088山師さん@トレード中 (ワッチョイWW 396c-ucrw)2018/01/17(水) 01:47:47.29ID:JFvOn6LU0>>85 治験からCVCが出てくるのか 増資引き受けではないんかな 0089山師さん@トレード中 (ワッチョイ 898e-5P5V)2018/01/17(水) 05:55:12.89ID:E1+qwUqw0 ※英国特許出願(Heptares):Novel GLP-1 Receptor Agonist Peptides. (1/10公開) ・Publication Number: GB 2551945 A (PCT) ・Publication Date: 2018/1/10 ・Applicants: Heptares Therapeutics Ltd Abstract: A compound of formula (I): (I) wherein Q is optionally substituted phenyl or monocyclic heteroaryl; x is an integer from 1 to 3; R1 & R2 are hydrogen or C1-6 alkyl, or form a ring; aa1 is an amino acid; G is glycinyl;T is L-threoninyl; aa2 is an amino acid; W is L-serinyl or 2,3-diaminopropionyl; aa3 is an amino acid; aa4 is an amino acid; aa5 is a linking group; Z is hydrogen, -COOR8 or -CONR9R10; R8, R9 and R10 are hydrogen or C1-6 alkyl; or a tautomeric or stereochemically isomeric form or a prodrug, salt or zwitterion thereof. The compounds of formula (I) are Glucagon-like peptide-1 (GLP-1) receptor agonist peptides and are useful in treating diseases or conditions mediated by insulin, such as diabetes mellitus type 1 or 2. The invention further relates to compositions containing said peptides and processes for their preparation. 0090山師さん@トレード中 (ワッチョイ 898e-5P5V)2018/01/17(水) 05:55:41.77ID:E1+qwUqw0 ※Doctors newspaper: COPD "We live in the age of dual bronchodilation!" (1/16) If it is possible to efficiently deflate the lungs of COPD patients, this can also increase cardiac output. This makes it easier for those affected to get more exercise again. BERLIN: Dual bronchodilation in COPD therapy has been upgraded. This is reflected, among other things, in the updated recommendations of the Global Initiative for COPD (GOLD). "We know that we can achieve a FEV1 increase of 300 to 350 ml with dual bronchodilation," explained Professor Marek Lommatzsch, University of Rostock. The decisive factor is not only that the respiratory tract is widened, but also that the lungs are blown out, according to the pneumologist at an event supported by Berlin-Chemie. This deflating was surprisingly strong, on average up to 700 ml. So the patient could take a deep breath, strain better. LAMA / LABA also strengthens heart: In addition, as the CLAIM study has shown, de-bloating also has a direct effect on the heart (ERS 2017, Abstract 2899). In the study of the group led by Professor Jens Hohlfeld, MH Hannover, 62 COPD patients with marked hyperinflation received a dual bronchodilator (indacaterol / glycopyrronium, 110/50 μg q.d.) or placebo. After 14 days, the change in the left ventricular end-diastolic volume was determined by means of magnetic resonance tomography. The LV volume improved significantly by 10.3 ml, cardiac output increased (> 0.2 l / min / m2). In addition, there was a bloating, the residual volume decreased on average by 750 ml (p <0.0001). "This study will make history," says Lommatzsch, because it shows that inhalative therapy improves cardiac output. Better cardiac output is often associated with increased activity. ・・・ 0091山師さん@トレード中 (ワッチョイ 898e-5P5V)2018/01/17(水) 05:56:13.30ID:E1+qwUqw0 ※The American Lawyer International: Paul Hastings, DLA Piper Expand Tokyo Offices. (1/16) Corporate partner Eiji Kobayashi has joined Paul Hastings from Norton Rose Fulbright, while Jones Day duo Kaoru Umino and Dan Matsuda have moved to DLA Piper. Paul Hastings and DLA Piper have expanded their Tokyo offices with lateral hires. Eiji Kobayashi has joined Paul Hastings from Norton Rose Fulbright, where he led the Tokyo office’s corporate practice. Kobayashi, along with two associates, will assist Paul Hastings’ Japanese clients on outbound acquisitions, cross-border investigations and compliance challenges, according to a statement. Kobayashi moved to Norton Rose Fulbright in 2015 from the Japanese firm Nishimura & Asahi, where he had led the cross-border transactions group. In 2015, he was part of the Norton Rose team representing Pfizer Inc. on a drug discovery collaboration with London-based Heptares Therapeutics Ltd. to develop new medicine. ・・・ According to data compiled by Thomson Reuters, Japan’s M&A volume totaled $142.2 billion in 2017, down 26.2 percent from a year earlier - its lowest level since 2014. Outbound deals from Japan, in particular, had a slow year, totaling $59.7 billion - a 38 percent decline from 2016. But inbound private equity deals targeting Japan hit $29.5 billion - their highest level since 1980, nearly triple the 2016 volume. 0092山師さん@トレード中 (ワッチョイ 898e-5P5V)2018/01/17(水) 05:57:05.45ID:E1+qwUqw0 ※Business Weekly Cambridge: Heptares and Imperial tackle gastrointestinal tract disease. (1/16) Sosei subsidiary Heptares Therapeutics has entered a new drug research and development collaboration with Imperial College London. The multi-year collaboration unites complementary teams at Heptares and Imperial seeking to rapidly advance drug discovery and translational research focused on multiple new and existing G protein-coupled receptor (GPCR) disease target opportunities associated with the gastro-intestinal tract. Heptares is set to relocate to a new 35,000 sq ft facility at Granta Park, Cambridge in-mid 2018 by which time local headcount should be up to 130. ・・・ 0093山師さん@トレード中 (ワッチョイ 898e-5P5V)2018/01/17(水) 05:57:40.75ID:E1+qwUqw0 ※Drug Profile: Research programme: GPCR targeting therapeutics - Heptares/Imperial College of Science Technology and Medicine. (1/16up) ・Latest Information Update: 16 Jan 2018 Alternative Names: ・Research programme - G protein-coupled modulators - Heptares/Imperial College of Science Technology and Medicine; ・Research programme - G protein-coupled modulators - Imperial College of Science Technology and Medicine/Heptares; ・Research programme: GPCR targeting therapeutics - Imperial College of Science Technology and Medicine/Heptares. At a glance: ・Originator: Heptares Therapeutics; Imperial College of Science, Technology and Medicine. ・Class: Small molecules. ・Mechanism of Action: G protein-coupled receptor modulators. ・Orphan Drug Status: No ・New Molecular Entity: Yes ・Highest Development Phases: Research Gastrointestinal disorders. Most Recent Events: ・10 Jan 2018, Heptares Therapeutics and Imperial College of Science Technology and Medicine agree to co-develop GPCR-targeting therapeutics for Gastro-intestinal disorders. ・10 Jan 2018, Early research in Gastrointestinal disorders in United Kingdom (unspecified route). 0094山師さん@トレード中 (ワッチョイ 898e-5P5V)2018/01/17(水) 05:58:09.29ID:E1+qwUqw0 ※R&D Agreement - 10 Jan 2018, Profile: Heptares Therapeutics, Imperial College of Science, Technology and Medicine. (1/16up) Drugs: Not related | Indications: Gastrointestinal disorders. ・In January 2018, Heptares Therapeutics and Imperial College of Science Technology and Medicine entered into a drug research and development collaboration to develop drug candidates designed to target multiple new and existing G protein-coupled receptors implicated in severe gastro-intestinal disorders. ・Under the terms of collaboration, Heptares will fund and support target discovery and validation and will be responsible for the progression and commercialisation of any compounds resulting from the collaboration. ・No further details were disclosed. 0095山師さん@トレード中 (ワッチョイ 898e-5P5V)2018/01/17(水) 06:00:14.85ID:E1+qwUqw0 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。 成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。 Heptares Approach Extends well Beyond our Growing Pipeline. UK be Relocating to the Cambridge Area in "July 2018." ・・・ ※ClinicalTrials: MEDI9447 EGFRm NSCLC Novel Combination Study(MEDI9447 with Osimertinib or AZD4635, AZD4635 with MEDI9447): "Start (Anticipated): 2018/2/9". (12/21update) ※Nature: "Structure of the complement C5a receptor bound to the extra-helical antagonist NDT9513727" (1/3) ※ClinicalTrials: AZD4635, Phase 1, Estimated Study Completion Date: August 23, 2019→Changed "August 13, 2019". "Phase 1b Protocol" Changed. (1/4update) ※SOSEI:Heptares社の研究者が炎症性疾患、神経変性疾患およびがんの重要な創薬ターゲットである補体C5a受容体の構造を解明。(1/5) ※SOSEI:サンフランシスコで開催の第36回JPモルガンAnnual Healthcare Conferenceにピーター・ベインズ出席。発表資料はイベント終了後公開。(1/5) ※Kymab Pipeline: KY1051: Discovery Research→"Pre-Clinical Development", KY1062 (New, Add): "Discovery Research" (1/6update) ※ScientificReports: "Towards high throughput GPCR crystallography: In Meso soaking of Adenosine A2A Receptor crystals." Single crystals and seven structures are reported here of which three are novel. (1/8) ※Scrip: Sosei CEO Says Recent $199m Equity Raising Will Help Pipeline Expansion: its shareholder base more international and will help finance the evolution of the group's proprietary pipeline. (1/8) ※BioWorld: Sosei lands $200M to fund six Heptares’ programs, including dementia. "placing to fund clinical development of proprietary assets discovered by its U.K. subsidiary, GPCR specialist Heptares." (1/9) ※医学界: 12/28、Ultibroは正式承認。中国で最初に承認された二重拡張薬になる。Ultibro承認の良いニュースは中国COPD患者の治療に新たな希望をもたらした。2018年に中国のCOPD治療領域が前進します!(1/9) ※Pluristem: FDA Clears Pluristem’s Expanded Access Program to Initiate Treatments of Critical Limb Ischemia Outside of Ongoing Phase III Study. the use of an investigational therapy outside of clinical trials. (1/9) ※SOSEI:インペリアル・カレッジ・ロンドンと消化器疾患治療薬の研究開発を目的とした共同研究開発契約を締結。この提携では当社およびHeptares社で実施中の創薬および開発プログラムの支援も行います。(1/11up) ※ClinicalTrials: FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine): Changed, Start: 2017/11/28→"2018/2/20", Changed, Completion Date: 2018/6/4→"2018/11/4". (1/12update) ※Pluristem: PLX Cells Significantly Inhibit Cancer Cell Growth in Newly Published Study. The results show significant reduction in tumor size as well as complete tumor remission in 30% of treated recipients. (1/12) ※The Biochemist: "UK industrial strategy and the life sciences sector." By Malcolm Weir, Founder, Chairman and CEO of Heptares. (1/15) ※SOSEI (English) Presentation Material: J.P. Morgan Healthcare Conference, 8 January 2018. ttp://v4.eir-parts.net/v4Contents/View.aspx?template=ir_material_for_fiscal_ym&sid=44192&code=4565 (1/16up) ※Heptares_HP_Publications: 4 Titles Add. (1/16update) ※Pluristem: Company Presentation January 2018: ttp://www.pluristem.com/wp-content/uploads/2016/04/Pluristem-January-2018.pdf (1/16up) ・・・ ※Translational Medicine in Zurich: "Novel Technologies Create New Molecules for Accessing Cutting-Edge Therapeutic Concepts": Andreas Pluckthun (1/22) ※Novartis Fourth Quarter and Full Year Results 2017: (1/24) ・・・ ※SOSEI 平成30年3月期第3四半期決算発表: (2月上旬予定) ・・・ 0096山師さん@トレード中 (ワッチョイ 898e-5P5V)2018/01/17(水) 06:00:53.72ID:E1+qwUqw0 ※SOSEIの成長相場の動向:成長戦略の進捗と共に予定通りに推移。笑。 Bloomberg:創薬ベンチャーのそーせいは買収を通じて業容を拡大し、株価は過去2年間で約300%上昇(2015/3/17終値_2972→2017/3/17終値10750)。 2015/_2/20 (終値_3780) 売残高14200 買残高 1530800 ・(2015/2/21Heptares子会社化: 2015/3/16※最安値2851)※[成功の序章ステージへ]→(2015/9/24※安値3550) 2015/10/30 (終値_4320) 売残高11400 買残高 2217900 ・ (2015/10/29※終値3885米国承認)※[次なる飛躍ステージへ] →(2015/11/30※終値_6060: Pfizer)※[上抜け圏へ] 2016/_4/25 (終値23230) 売残高39800 買残高 3404900 ・(2016/4/6終値14180:Allergan)※[強気相場へ]→(2016/5/9※最高値26180)→ 2016/_6/24 (終値14720) 売残高10500 買残高 2486100 ・(2016/6/24安値12960)※[強気相場解除]→※[時間軸での調整局面へ] ※2016年大納会(2016/12/30終値13450) _1/_6 (終値14030) 売残高__300 買残高 2907100 ・(2017/1/24安値12910、2/13安値12400)※[強気相場解除後の時間軸調整は順調に推移] _3/31 (終値10880) 売残高_5600 買残高 2621800 ・(3/1安値10380、4/4安値10280、5/23安値10810、6/7安値10960)※[振るい場・拾い場へ] _9/_8 (終値_8700) 売残高_1900 買残高 2037800 ・(7/31安値11280、8/24,29安値_8860、9/6※最安値_8590)※[拾い場も順調に推移] _9/15 (終値_8850) 売残高____0 買残高 2002400 ・(9/11安値_8630) _9/22 (終値_9200) 売残高__100 買残高 2021100 ・(9/19,20安値_8820) _9/29 (終値_9500) 売残高_1000 買残高 1961700 ・(9/26安値_8960) 10/_6 (終値_9540) 売残高__400 買残高 1881200 ・(10/4安値_9090) 10/13 (終値10200) 売残高_3000 買残高 1753000 ・(10/10安値_9570) 10/20 (終値_9810) 売残高____0 買残高 1746900 ・(10/19安値_9740) 10/27 (終値10230) 売残高__100 買残高 1644400 ・(10/23安値_9820) 11/_2 (終値11090) 売残高__200 買残高 1552700 ・(10/31安値10170) 11/10 (終値11230) 売残高__800 買残高 1574300 ・(11/8安値10310) 11/17 (終値12190) 売残高_3100 買残高 1532100 ・(9/11安値_8630、10/4安値_9090、11/8安値10310)※[時間軸調整終盤、予定通りに推移] 11/24 (終値11460) 売残高____0 買残高 1724600 ・(11/22安値11170) 12/_1 (終値10890) 売残高__100 買残高 1812600 ・(11/30安値10800) 12/_8 (終値10100) 売残高__900 買残高 1849800 ・(12/6安値_9970) 12/15 (終値10870) 売残高__900 買残高 1763800 ・(12/11安値10070) 12/22 (終値10550) 売残高__300 買残高 1724500 ・(12/22安値10530) 12/29 (終値10940) 売残高__300 買残高 1634900(_-89600) ※2017年大納会(安値10730) _1/12 (終値11700) 売残高_3400 買残高 1507400(-127500)※1/16up (安値11470) ※2018年大発会(1/4終値10800) ・(1/5安値10530) (1/9安値10760) _1/16 (終値11740) 5日線乖離(+0.14%) 25日線乖離(+7.75%) 75日線乖離(+11.21%) 200日線乖離(+9.00%) (安値11380) 0097山師さん@トレード中 (ワッチョイ 898e-5P5V)2018/01/17(水) 06:01:34.93ID:E1+qwUqw0 ※Technical Analysis Charts : ttps://www.zonebourse.com/zbcache/charts/ObjectChart.aspx?Name=6814799&Type=Custom&Intraday=1&Width=980&Height=650&Cycle=WEEK1&Duration=120&TopMargin=10&Render=Candle&ShowName=0&Company=4Traders_us